Adverum is a clinical-stage AAV-based gene therapy company targeting unmet medical needs in ocular and rare diseases. We are seeking a highly motivated researcher to contribute to the development of innovative gene therapies in the nonclinical research group. The successful candidate will conduct internal and external nonclinical studies to generate proof of concept as well as evaluate tolerability of novel gene therapy candidates.
What you'll do:
- Conduct nonclinical development activities (pharmacology and toxicology) for IND-enablement of gene therapy products.
- Design, manage and conduct nonclinical hands-on studies (GLP and non-GLP) for inclusion in regulatory submissions, including pharmacology, toxicology, and biodistribution studies.
- Hands-on nonclinical studies and vivarium management at a site off of Adverum's campus - this will occupy the majority of your time.
- Collaborate with members of research team to evaluate early gene therapy candidates in animal models of ocular diseases.
- Serve as an intellectual, technical and hands-on expert in animal models of human diseases.
- Train, assist and collaborate with other nonclinical and research team members
- Serve as a liaison between Adverum and external in vivo facility management and staff.
- Author and submit IACUC protocols and obtain approvals.
- Ensure compliance of the internally conducted nonclinical studies with IACUC protocols and LSBS practices.
- Work closely with the nonclinical study monitoring team to ensure that planning and execution of the outsourced projects adhere to the highest standards.
- Write and edit nonclinical study protocols and study reports.
- Prepare and edit nonclinical documents for regulatory submission, in collaboration with manager.
- Facilitate and execute nonclinical development plans for future pipeline products.
- Prepare materials for presentation and present the data to group and company leadership, as well as at the external meetings and conferences.
- Maintain current understanding of gene therapy field, as well as the scientific literature related to specific drug discovery projects.
About you:
- PhD degree or equivalent in pharmaceutical sciences, life sciences, pharmacology or veterinary sciences with overall 12+ years of experience in industrial and/or academic research, including 5+ years in the pharmaceutical industry environment.
- Expertise in small animal surgical technique
- Hands on experience in the development of animal models. Experience in animal models of ocular diseases is desired.
- Ability to plan independently and execute experiments, develop reagents, methods and assays, record and interpret data, and succinctly communicate results in oral and written form.
- Vivarium operations management experience.
- Ability to work in heavily matrixed environment, through productive development and maintenance of interdisciplinary collaborative networks.
- Integrate and critically analyze data sets.
About Us
Adverum is a clinical-stage gene therapy company targeting unmet medical needs in ophthalmology and rare diseases. Adverum develops gene therapy product candidates designed to provide durable efficacy by inducing sustained expression of a therapeutic protein. Adverum’s core capabilities include clinical development, novel vector discovery and in-house manufacturing expertise, specifically in scalable process development, assay development, and current Good Manufacturing Practices quality control.
At Adverum, Inclusion and Diversity are at our core. We believe in the power of being your authentic self. We strive to create the space which allows for everyone in our Adverum Community to not only feel safe but encouraged to speak, learn from each other, grow in their professions and be the very best versions of themselves no matter what their age, ethnic background, gender, origin, religion or sexual orientation
What We Do
Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing functional cures to restore vision and prevent blindness. Leveraging the research capabilities of its proprietary, intravitreal (IVT) platform, Adverum is developing durable, single-administration therapies, designed to be delivered in physicians’ offices, to eliminate the need for frequent ocular injections to treat these diseases. Adverum is evaluating its novel gene therapy candidate, ixoberogene soroparvovec (Ixo-vec, formerly referred to as ADVM-022), as a one-time, IVT injection for patients with neovascular or wet age-related macular degeneration. By overcoming the challenges associated with current treatment paradigms for these debilitating ocular diseases, Adverum aspires to transform the standard of care, preserve vision, and create a profound societal impact around the globe.
